Talazoparib-Enzalutamide Improves Radiographic PFS in Certain Prostate Cancer

Written By Aaron Tallent

Overcoming Misinformation Starts With 1 Person at a Time

This Oncology News Central article covers phase 3 TALAPRO-3 trial results showing that talazoparib plus enzalutamide improved radiographic progression-free survival in men with HRR gene-altered metastatic castration-sensitive prostate cancer

Learn more
Aaron Tallent
Previous

New Playbook Offers Primary Care Practices a Roadmap for AI Adoption
Next

GLP-1 RA Exposure After Diagnosis Could Lead to Reduced Progression, Improved Survival in Multiple Malignancies